EP4190802A4 - Nouveau peptide de pénétration cellulaire et utilisation associée - Google Patents
Nouveau peptide de pénétration cellulaire et utilisation associée Download PDFInfo
- Publication number
- EP4190802A4 EP4190802A4 EP21842399.4A EP21842399A EP4190802A4 EP 4190802 A4 EP4190802 A4 EP 4190802A4 EP 21842399 A EP21842399 A EP 21842399A EP 4190802 A4 EP4190802 A4 EP 4190802A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- penetrating peptide
- cell penetrating
- peptide
- cell
- penetrating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/101—Plasmid DNA for bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010692443 | 2020-07-17 | ||
| PCT/CN2021/106043 WO2022012539A1 (fr) | 2020-07-17 | 2021-07-13 | Nouveau peptide de pénétration cellulaire et utilisation associée |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4190802A1 EP4190802A1 (fr) | 2023-06-07 |
| EP4190802A4 true EP4190802A4 (fr) | 2024-04-03 |
Family
ID=79556027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP21842399.4A Pending EP4190802A4 (fr) | 2020-07-17 | 2021-07-13 | Nouveau peptide de pénétration cellulaire et utilisation associée |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230287086A1 (fr) |
| EP (1) | EP4190802A4 (fr) |
| JP (1) | JP7834294B2 (fr) |
| CN (1) | CN115461358A (fr) |
| WO (1) | WO2022012539A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113138276B (zh) * | 2020-01-19 | 2022-09-16 | 厦门万泰凯瑞生物技术有限公司 | 用于检测HBcAg的方法及抗体 |
| CN116712554A (zh) * | 2023-06-08 | 2023-09-08 | 江苏靶标生物医药研究所有限公司 | 一种穿膜肽l17e以非融合形式递送蛋白质分子的递送方法 |
| CN116555197B (zh) * | 2023-06-25 | 2023-09-01 | 中国科学院深圳先进技术研究院 | 一种沙门氏菌工程穿膜噬菌体及其构建方法与应用 |
| CN117069799B (zh) * | 2023-08-29 | 2025-07-08 | 百葵锐(深圳)生物科技有限公司 | 细胞穿膜肽及其应用 |
| WO2025250808A1 (fr) * | 2024-05-29 | 2025-12-04 | The Brigham And Women’S Hospital, Inc. | Compositions et méthodes d'administration anti-crispr |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009034182A1 (fr) * | 2007-09-14 | 2009-03-19 | Institut Pasteur | Polynucleotides permettant l'expression et la secretion d'un pseudo-virus recombine contenant des epitopes etrangers, production et utilisation de ces polynucleotides |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2328457A1 (fr) | 1998-06-20 | 1999-12-29 | Washington University | Complexes peptidiques de permeation membranaire destines a l'imagerie medicale, au diagnostic et a la therapie pharmaceutique |
| CN101052414B (zh) * | 2000-08-16 | 2012-10-10 | 塞尔德克斯医疗有限公司 | 具有增强的稳定性的免疫原性HBc嵌合体颗粒 |
| US7320795B2 (en) * | 2003-07-30 | 2008-01-22 | Vaccine Research Institute Of San Diego | Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof |
| CN101612405A (zh) * | 2008-06-26 | 2009-12-30 | 中国人民解放军第三〇二医院 | 一种乙肝病毒前c-c基因疫苗的制备及应用 |
| WO2010042743A2 (fr) * | 2008-10-08 | 2010-04-15 | Chimeros Inc. | Multiplexes chimères, compositions et procédés permettant de les utiliser |
| RU2555346C2 (ru) * | 2009-08-07 | 2015-07-10 | Трансген Са | Композиция для лечения инфекции вирусом гепатита в |
| EA032364B1 (ru) * | 2011-02-11 | 2019-05-31 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Молекула нуклеиновой кислоты, кодирующая коровый белок вируса гепатита в, и вакцина, содержащая указанную молекулу |
| CN103243172B (zh) | 2012-02-03 | 2015-02-04 | 中国科学院上海药物研究所 | 抗hbv的化合物的筛选方法 |
| ES2981865T3 (es) | 2012-07-11 | 2024-10-10 | Gemvax & Kael Co Ltd | Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo |
| WO2014124047A1 (fr) | 2013-02-06 | 2014-08-14 | Academia Sinica | Peptides antimicrobiens issus du domaine riche en arginine de la protéine cœur du virus de l'hépatite b |
| CN104710534B (zh) * | 2015-02-12 | 2018-02-09 | 重庆医科大学 | 重组HBc融合蛋白 |
| JP6863966B2 (ja) * | 2015-08-25 | 2021-04-21 | シャアメン ユニバーシティ | 標的ポリペプチドを提示するためのポリペプチド担体及びその使用 |
-
2021
- 2021-07-13 WO PCT/CN2021/106043 patent/WO2022012539A1/fr not_active Ceased
- 2021-07-13 CN CN202180031071.6A patent/CN115461358A/zh active Pending
- 2021-07-13 JP JP2023503066A patent/JP7834294B2/ja active Active
- 2021-07-13 EP EP21842399.4A patent/EP4190802A4/fr active Pending
- 2021-07-13 US US18/005,543 patent/US20230287086A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009034182A1 (fr) * | 2007-09-14 | 2009-03-19 | Institut Pasteur | Polynucleotides permettant l'expression et la secretion d'un pseudo-virus recombine contenant des epitopes etrangers, production et utilisation de ces polynucleotides |
Also Published As
| Publication number | Publication date |
|---|---|
| US20230287086A1 (en) | 2023-09-14 |
| JP7834294B2 (ja) | 2026-03-24 |
| JP2023534054A (ja) | 2023-08-07 |
| WO2022012539A1 (fr) | 2022-01-20 |
| EP4190802A1 (fr) | 2023-06-07 |
| CN115461358A (zh) | 2022-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4190802A4 (fr) | Nouveau peptide de pénétration cellulaire et utilisation associée | |
| EP4209494C0 (fr) | Composé de peptide court de proline à cycle modifié et son utilisation | |
| EP4410818A4 (fr) | Peptide possédant une activité anti-vieillissement, et son utilisation | |
| EP4349871A4 (fr) | Polypeptide et son utilisation | |
| EP4428232A4 (fr) | Protéine de cas13 isolée et son utilisation | |
| EP4353249A4 (fr) | Multi-agoniste et son utilisation | |
| EP4253423A4 (fr) | Protéine recombinante bispécifique et son utilisation | |
| EP3712268A4 (fr) | Cellule humaine transformée et son utilisation | |
| EP4136101A4 (fr) | Polypeptides interleukine-22 génétiquement modifiés et leurs utilisations | |
| EP4401752A4 (fr) | Peptides antimicrobiens modifiés et leur utilisation | |
| EP4444324A4 (fr) | Récepteurs de lymphocytes t modifiés et leurs utilisations | |
| EP4069715A4 (fr) | Peptides et leur utilisation dans le traitement d'une inflammation | |
| EP4453020A4 (fr) | Polypeptides lilrb et leurs utilisations | |
| EP3564255A4 (fr) | Nouveau peptide à double fonction ayant une perméabilité cellulaire et une capacité de régénération de tissu osseux et utilisation de celui-ci | |
| EP4434536A4 (fr) | Peptide agrafé et son utilisation | |
| EP4501943A4 (fr) | Peptide ayant une activité antidiabétique, complexe peptidique et son utilisation | |
| EP4043076C0 (fr) | Peptide cyclique possédant une activité inhibitrice de ctla-4 et application de celui-ci | |
| EP3789396C0 (fr) | Peptide synthétique sp2 et son utilisation | |
| EP4365186A4 (fr) | Peptide ayant une activité antidiabétique et son utilisation | |
| EP4501344A4 (fr) | Peptide présentant des activités anti-inflammatoires et antifibrotiques et son utilisation | |
| EP4321527A4 (fr) | Variant peptidique de pénétration cellulaire et son utilisation | |
| EP3565823C0 (fr) | Peptides du s-arrestin et leur utilisation thérapeutique | |
| EP4259221C0 (fr) | Constructions thymiques et leurs utilisations | |
| EP4209505A4 (fr) | Composition comprenant un peptide, et son utilisation | |
| EP4428143A4 (fr) | Peptide ayant des activités physiologiques et son utilisation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20230131 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230628 |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: C07K0014020000 Ipc: A61K0009060000 |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20240306 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 9/22 20060101ALI20240229BHEP Ipc: A61K 38/00 20060101ALI20240229BHEP Ipc: A61K 47/42 20170101ALI20240229BHEP Ipc: A61K 47/64 20170101ALI20240229BHEP Ipc: A61K 9/06 20060101AFI20240229BHEP |